Last reviewed 2026-04-20 · How we verify

Cospanon (FLOPROPIONE)

Phase 2 active Small molecule

Cospanon (generic name: FLOPROPIONE) is a drug. It is currently in Phase 2 development for Biliary dyskinesia, Calculus in biliary tract.

FLOPROPIONE works by inhibiting the enzyme Catechol O-methyltransferase, which plays a role in the regulation of bile flow.

FLOPROPIONE, also known as Cospanon, is a small molecule modality targeting Catechol O-methyltransferase. It is used to treat biliary dyskinesia and calculus in the biliary tract. The current owner of Cospanon is unknown, and its commercial status is unclear. Further information on its pharmacokinetics and safety profile is also unavailable.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FLOPROPIONE
Target	Catechol O-methyltransferase
Modality	Small molecule
Therapeutic area	Dermatology
Phase	Phase 2

Mechanism of action

Think of bile like a delivery truck that carries waste from your liver to your intestines. Catechol O-methyltransferase is like a traffic cop that helps control the flow of these trucks. By blocking this traffic cop, FLOPROPIONE helps improve the flow of bile and relieve symptoms of biliary dyskinesia and calculus.

Approved indications

Biliary dyskinesia
Calculus in biliary tract

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cospanon CI brief — competitive landscape report
Cospanon updates RSS · CI watch RSS

Frequently asked questions about Cospanon

What is Cospanon?

Cospanon (FLOPROPIONE) is a Small molecule drug, indicated for Biliary dyskinesia, Calculus in biliary tract.

How does Cospanon work?

FLOPROPIONE works by inhibiting the enzyme Catechol O-methyltransferase, which plays a role in the regulation of bile flow.

What is Cospanon used for?

Cospanon is indicated for Biliary dyskinesia, Calculus in biliary tract.

What is the generic name of Cospanon?

FLOPROPIONE is the generic (nonproprietary) name of Cospanon.

What development phase is Cospanon in?

Cospanon is in Phase 2.

What does Cospanon target?

Cospanon targets Catechol O-methyltransferase.

Target: All drugs targeting Catechol O-methyltransferase
Therapeutic area: All drugs in Dermatology
Indication: Drugs for Biliary dyskinesia
Indication: Drugs for Calculus in biliary tract

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing